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year, target lesion failure was 5.0% (11/220), and comprised of target
lesion revascularization 2.3% (5/220), cardiac death 1.4% (3/220), and
target vessel myocardial infarction 2.3% (5/220). ARC deﬁnite/prob-
able stent thrombosis was 0.9% (2/220) at one year. Outcomes at 12
months were also similar in patients with and without DM (Figure).
CONCLUSIONS The RESOLUTE INTEGRITY US study included a large
number of diabetic patients and patients with complex anatomy. Use
of Resolute Integrity ZES was associated with excellent device success
and clinical outcomes, including in patients with diabetes mellitus, at
one year. Two-year outcomes will be available at the time of TCT 2015.
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BACKGROUND The beneﬁts of new-generation drug eluting stents
(DES) in women with multiple atherothrombotic risk factors are
unclear.
METHODS The purpose of the current study was to investigate: (i) the
impact of high atherothrombotic (AT) risk on clinical outcomes in
women undergoing percutaneous coronary intervention (PCI) with
drug-eluting stent (DES) and (ii) the effect of new-generation DES,
compared with early-generation, in women with versus without high
AT risk. We pooled patient-level data for women enrolled in 26 ran-
domized trials. Study population was categorized based on the pres-
ence or absence of high AT risk, which was deﬁned as having history
of diabetes mellitus, prior percutaneous or surgical revascularization,
or prior myocardial infarction (MI). The primary endpoint was majoradverse cardiovascular events (MACE) at 3 years, deﬁned as the
composite of death, MI, target lesion revascularization or stent
thrombosis. Women who received a bare-metal stent were excluded
from this analysis.
RESULTS Out of 10,449 women included in the pooled database, 5333
(51%) had high AT risk. A signiﬁcantly higher crude rates of 3-year
MACE was observed in women with versus without high AT risk (15.8
% vs. 10.6%; p < 0.0001). Following multivariable adjustment, high
AT risk was independently associated with higher 3-year risk of MACE
(HR: 1.50; 95% CI: 1.23 – 1.83; p <0.0001) and all-cause mortality (HR:
1.69; 95% CI: 1.18 – 2.38; p ¼ 0.003). Compared with early-generation
DES, in women at high AT risk, the use of new-generation DES was
associated with signiﬁcantly lower risk of MACE at 3 years (HR:0.79;
95% CI:0.63-0.99; p ¼ 0.04). New-generation DES had no signiﬁcant
effect on all-cause mortality in high AT risk women (HR: 0.69; 95% CI:
0.47 – 1.02; p ¼ 0.06).The effect of new-generation DES was uniform
between high and non-high AT risk women, without evidence of
interaction.
CONCLUSIONS Use of new-generation DES in women with multiple
risk factors for atherothrombosis is associated with a lower risk for
long-term adverse ischemic events compared with early-generation
DES.
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BACKGROUND Predictive factors of atherothrombotic events in
women after implantation of drug eluting stents (DES) are unclear.
Prior studies of this subject were conducted on predominantly male
patient populations.
METHODS The objective of the current study was to investigate the
predictive factors of atherothrombotic events in female patients with
DES relative to the time when these events occurred. We pooled pa-
tient-level data from 26 randomized controlled trials of DES. The
primary endpoint was the risk of intracoronary thrombotic event (ITE)
at 3 years, deﬁned as the composite of stent thrombosis or myocardial
infarction. The timing of ITEs was subdivided into early (occurring 
30 days after DES placement), late (31 days to 1 year), and very late (>1
year). Predictive factors of ITEs were analyzed via multivariable Cox
regression models at each time point. Women who received a bare
metal stent were excluded from this analysis.
RESULTS Out of 10,449 women in the pooled dataset, 345 (3.0%) had
an early ITE, 113 (1.0%) had a late ITE, and 133 (1.0%) had a very late
ITE. Per the multivariable analysis, the independent predictors for
cumulative ITE at 3 years were patient age (per year increase; HR: 1.01;
95%CI: 1.00-1.02; p¼0.05), diabetes mellitus (HR: 1.39; 95% CI:1.12-
1.73; p¼0.003), arterial hypertension (HR: 1.41; 95% CI: 1.05-1.91;
p¼0.02), previous percutaneous coronary intervention (HR: 1.35; 95%
CI: 1.05-1.75; p¼0.02), use of ﬁrst-generation DES (HR: 1.30; 95% CI:
1.02-1.65; p¼0.03), multivessel disease (1.29; 95% CI: 0.99-1.67;
p ¼0.05), number of stents implanted (per additional stent implanted;
